AstraZeneca's Amyloid Miss, Vertex's $10B Crinetics Buy, and Kidney Disease's Two-Drug Race – This Week in Biotech #108
Eplontersen fails in a market its competitors already own, Vertex makes its biggest deal ever to diversify beyond cystic fibrosis, and Vera Therapeutics prices Trutakna at a premium (July 3-9, 2026).
Welcome back to This Week in Biotech by Biotech Blueprint, edition 108, covering biotech and pharma news from July 3 to July 9, 2026.
Last week, I launched the Biotech Blueprint merch store. The limited subscription special is running for one more week (ends July 16). Sign up for annual subscription and pick a free T-shirt of your choice. Visit the store at https://biotechblueprint.printify.me/ to see available designs, colors, and sizes.
Democratizing drug development
From bespoke labs to systemic change. Explore tools to accelerate in vivo genomic medicine development.
🎙️ Biotech Blueprint brings you weekly video updates on the latest biotech and pharma news, plus in-depth podcast interviews with industry leaders. You can find us on YouTube, Spotify, and Apple Podcasts. If you want to be featured on our podcast, get in touch.
🌐 For consulting inquiries, please email us or visit BiotechBlueprintConsulting.com.
👥 If you haven’t already, please connect with me or follow me on LinkedIn.
VIDEO SUMMARY
The video recording platform didn’t record the first few seconds so apologies and Welcome back to Biotech Blueprint :)
THIS WEEK’S KEY TAKEAWAYS 🔑
The biggest story this week was a failure. AstraZeneca and Ionis’s eplontersen missed the primary endpoint of the Phase 3 CARDIO-TTRansform trial in transthyretin amyloid cardiomyopathy, a fatal heart-muscle disease. The market reaction told the story. AstraZeneca fell 8%, Ionis fell 21%, and rivals Alnylam and BridgeBio both jumped double digits. What actually happened is that the standard of care caught up to the trial. By the time CARDIO-TTRansform read out, 57% of patients were already on a protein-stabilizer drug (Pfizer’s Vyndamax or BridgeBio’s Attruby) at baseline, and another 24% started one during the study. Eplontersen worked (29% risk reduction) only in the shrinking group taking nothing else. In transthyretin amyloid cardiomyopathy, a fourth entrant now has to beat a background of drugs that already work, not placebo. Alnylam and BridgeBio didn’t win because they ran a better trial this week but because they were already on the field.
Vertex spent $10 billion this week, its largest deal ever, to buy Crinetics and move beyond the cystic fibrosis franchise that still generates more than $10 billion a year. The same dynamic showed up in kidney disease, where Vera Therapeutics won accelerated FDA approval for Trutakna (atacicept) in immunoglobulin A nephropathy, the second drug of its kind to market after Otsuka’s Voyxact, but with the deeper dataset and a higher price. In both cases the message is the same. Being first is worth less than being better and payers will price the difference.
Two other themes worth flagging this week. First, obesity is truly shifting from an efficacy story to a tolerability story. Kailera and Hengrui’s oral GLP-1 pill hit its Phase 3 goals in China but with nausea and vomiting rates near 70%, which one analyst called alarming. Second, the pace of Western deals with Chinese biotechs isn't slowing down, even as Washington moves to restrict them. AstraZeneca and GSK both signed deals with Sino Biopharmaceutical this week, adding to roughly 100 Western-Chinese transactions since early 2025, the exact pattern that new legislation is trying to slow.
Finally, individualized medicine got real money. ARPA-H committed up to $160 million to seven labs to build custom gene-editing treatments for rare diseases, an attempt to turn the one-off “Baby KJ” success into a repeatable process. In the same week, Prime Medicine won an arbitration ruling against Beam that clears its lead gene-editing program to keep moving. Custom, one-off gene editing is starting to move from proof of concept to actual funded infrastructure.
Biotech/Pharma News 🧬
🔹 Vertex agreed to acquire Crinetics for $85 per share in cash, a 102% premium and the fourth largest biotech acquisition of 2026. The two endocrine drugs Vertex is buying are Palsonify (paltusotine), an oral therapy for acromegaly approved in September 2025 that pulled in $10M in Q1 revenue and is pacing toward roughly $70M this year, and atumelnant, a late stage candidate for congenital adrenal hyperplasia and Cushing’s syndrome. Vertex projects combined peak sales above $5B. This is the clearest statement yet that Vertex intends to become a multi-franchise specialty company rather than the cystic fibrosis only company it has been, adding endocrinology to recent moves in pain (Journavx) and kidney disease. Not everyone loved the price. Stifel called the deal a bet on the “bullish case,” flagging competition from Pfizer and Novartis on the acromegaly side and Neurocrine’s Crenessity against atumelnant, and Vertex stock ticked down on the news. Vertex is sitting on cystic fibrosis cash and facing eventual competition there, so the calculation is that overpaying for de-risked commercial and near-commercial assets today beats waiting. Closing is expected in Q3.
🔹 The FDA granted accelerated approval to Vera Therapeutics’ Trutakna (atacicept) to reduce proteinuria in adults with primary immunoglobulin A nephropathy, a progressive kidney disease affecting about 160k Americans. Trutakna is a once weekly self-injected antibody that blocks two immune signals, BAFF and APRIL, and is the first approved drug to hit both. In the ORIGIN 3 trial it cut urine protein 46% from baseline at 36 weeks, a 42% reduction versus placebo. Because this is accelerated approval based on a surrogate endpoint, Vera still has to prove the drug preserves kidney function over time, with confirmatory data expected in Q3. The commercial fight is a head to head with Otsuka’s Voyxact, which reached market last year and targets APRIL alone with monthly dosing. Vera priced Trutakna at $425k a year against Voyxact’s roughly $390k, betting that a broader mechanism and a stronger dataset justify the premium. Two drugs competing on data quality and dosing convenience rather than novelty is the market Vera has just entered.
🔹 GSK terminated its neurodegeneration alliance with Alector, ending a partnership once worth up to $2.2B (including a $700M upfront in 2021). Both assets failed. Latozinemab, a progranulin-boosting antibody for frontotemporal dementia in patients with specific mutations, failed to slow disease in its late stage trial last October, and Alector halted a Phase 2 study of nivisnebart in early Alzheimer’s on a futility analysis in April. The collapse is a real setback for GSK’s tentative return to brain diseases after more than a decade on the sidelines. For Alector it’s closer to a survival question. The company also lost a separate AbbVie collaboration, has cut staff repeatedly, and has seen its stock fall about 95% over five years. Progranulin biology has been one of neurology’s more credible genetic hypotheses for years, but it hasn’t translated into a disease-modifying win, and large cap partners are no longer willing to keep paying to find out.
🔹 Two of the biggest UK drugmakers signed China deals in the same week. AstraZeneca paid $200M upfront, with up to $1.9B in milestones plus royalties, for ex-China rights to TQC3721, a Sino Biopharmaceutical inhaled lung drug that has cleared Phase 2 in chronic obstructive pulmonary disease with better lung function than standard therapy. That positions AstraZeneca against Merck’s Ohtuvayre, which Merck acquired by paying $10B for Verona Pharma. GSK separately handed Sino the China rights to distribute its marketed respiratory drugs Trelegy (£3 billion in 2025 global sales) and Anoro. These deals land in the middle of roughly 100 Western-Chinese pharma deals since early 2025, and the exact scrutiny that count has provoked. Proposed US legislation would subject outbound investment in Chinese biotech to national-security review. Even as policymakers try to slow the China licensing channel, the economics keep winning. Faster, cheaper, later-stage assets are enough for big pharma to keep signing.
🔹 MeiraGTx secured up to $400M from Oberland Capital in a royalty and financing arrangement to support its late stage eye gene therapies, one of which it recently reacquired from Johnson & Johnson (bota-vec, for X-linked retinitis pigmentosa). The interesting part is the structure. This is another example of revenue and launch-stage biotech reaching for non-dilutive private capital (royalty monetization, structured credit) rather than selling shares, even with public markets wide open. It follows the same logic as BridgeBio’s $1B preferred equity for its amyloidosis launch and Blackstone’s royalty deals. For companies with visible commercial catalysts, giving up future royalties looks cheaper than giving up equity today.
🔹 ARPA-H committed up to $160M through a program called THRIVE to seven research teams building custom gene-editing treatments for rare diseases across multiple organ systems, with the teams required to reach the clinic by year three. THRIVE is an explicit bet that the widely covered “Baby KJ” case, in which an infant received a one of a kind editing therapy, can become a repeatable manufacturing and regulatory pathway rather than a single exception. Custom, N of 1 gene editing has been the frontier the field has been circling for years. Federal money is now trying to industrialize it.
🔹 The White House is reviewing three finalists to run the FDA, suggesting a decision may finally be near after months without a permanent commissioner since Marty Makary’s May departure. In parallel, the agency paused its practice of publicly releasing the letters that explain why it rejects drugs, following a citizen petition from an unnamed pharma company, while it works to formalize the policy. The transparency reversal is small but telling. The short-lived experiment in publishing complete response letters, meant to demystify rejections, is on hold. And the leadership vacuum that has shadowed PDUFA timing all summer may soon lift. Both matter for how predictable the regulatory path looks in the back half of 2026.
Have a great rest of your week and thanks for reading Biotech Blueprint!
DISCLAIMER: This publication is for informational and educational purposes only and does not constitute investment, legal, medical, or tax advice, a solicitation, or an offer to buy/sell any security. Information is believed reliable but no warranty is made as to accuracy or completeness; views may change without notice. Do your own research and consult qualified professionals.
DISCLOSURE & CONFLICTS: The author may hold positions in securities mentioned and may change positions at any time without notice. No compensation is received from companies mentioned, and there are no known material business relationships unless explicitly stated. Content may reference clinical data and regulatory events; always consult primary sources and a licensed clinician for medical decisions. Past performance is not indicative of future results.
LIABILITY: Use of this content is at your own risk. The author assumes no responsibility for any losses arising from reliance on this material.
Image source: ChatGPT